Scopus BioPharma Inc.
SCPS evidence brief
What we can confirm
- BioSniper Score:
- 5.0 / 10
- Market Cap:
- $17K
- Lead Asset:
- duet-01 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for SCPS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$17K
Cash Runway
—
Lead Asset
duet-01 (Phase 1)
Next Catalyst
—
Tracking 3 pipeline candidates for Scopus BioPharma Inc..
Run Scopus BioPharma Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Scopus BioPharma Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 1
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Short Interest
as of Apr 29, 2026- % of float
- 0.3%
- Days to cover
- 0.2
- Shares short
- 23,773
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SCPS short interestFrequently asked questions
What is Scopus BioPharma Inc.'s lead drug candidate?
Scopus BioPharma Inc.'s most advanced tracked candidate is duet-01 (Phase 1) for B-cell non-Hodgkin lymphoma.
Who is the CEO of Scopus BioPharma Inc.?
Dr. Alan D. Horsager Ph.D. is the chief executive officer of Scopus BioPharma Inc. (SCPS).
Where is Scopus BioPharma Inc. headquartered?
Scopus BioPharma Inc. (SCPS) is headquartered in New York, NY, United States.
What therapeutic areas does Scopus BioPharma Inc. focus on?
Scopus BioPharma Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.